SUPERNUS PHARMACEUTICALS, INC. Stockholders Equity

Quick Answer

SUPERNUS PHARMACEUTICALS, INC. reported Stockholders Equity of $1.06 billion for the year ending 2025.

  • SUPERNUS PHARMACEUTICALS, INC. showed an increase of +2.5% in Stockholders Equity from 2024 to 2025.
  • This data is from SUPERNUS PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
  • XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Quarterly values from 10-Q filings: Q1 2015: $94.58 million | Q2 2015: $102.37 million | Q3 2015: $109.44 million | Q1 2016: $128.14 million | Q2 2016: $141.02 million | Q3 2016: $173.37 million | Q1 2017: $206.06 million | Q2 2017: $229.40 million | Q3 2017: $251.66 million | Q1 2018: $351.87 million | Q2 2018: $390.49 million | Q3 2018: $421.94 million | Q1 2019: $480.02 million | Q2 2019: $522.90 million | Q3 2019: $557.26 million | Q1 2020: $613.38 million | Q2 2020: $665.97 million | Q3 2020: $708.88 million | Q1 2021: $754.44 million | Q2 2021: $785.58 million | Q3 2021: $810.47 million | Q1 2022: $828.45 million | Q2 2022: $841.43 million | Q3 2022: $852.80 million | Q1 2023: $912.15 million | Q2 2023: $919.91 million | Q3 2023: $912.19 million | Q1 2024: $929.17 million | Q2 2024: $957.45 million | Q3 2024: $1.01 billion | Q1 2025: $1.03 billion | Q2 2025: $1.06 billion | Q3 2025: $1.05 billion.
  • Over the full 14 years of available data (2012 to 2025), SUPERNUS PHARMACEUTICALS, INC.'s Stockholders Equity has grown by 1,744.2%.
  • Historical annual values: Fiscal year 2025: $1.06 billion | Fiscal year 2024: $1.04 billion | Fiscal year 2023: $921.52 million | Fiscal year 2022: $886.20 million | Fiscal year 2021: $815.85 million | Fiscal year 2020: $744.86 million | Fiscal year 2019: $595.43 million | Fiscal year 2018: $453.02 million | Fiscal year 2017: $267.48 million | Fiscal year 2016: $191.76 million | Fiscal year 2015: $88.01 million | Fiscal year 2014: $40.70 million | Fiscal year 2013: $33.46 million | Fiscal year 2012: $57.57 million.
  • Data sourced from SEC EDGAR public filings as of August 6, 2026.

Last verified: